Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Immunization
Research on immunization reported by scientists at University of Cape Town, Institute of Infectious Diseases and Molecular Medicine
September 3rd, 2008
Current study results from the report, 'Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa,' have been published. According to recent research published in the Journal of Infectious Diseases, "The efficacy of bacille Calmette-Guérin (BCG) may be enhanced by heterologous vaccination strategies that boost the BCG-primed immune response. One leading booster vaccine, MVA85A (where 'MVA' denotes 'modified vaccinia virus Ankara'), has shown promising safety and immunogenicity in human trials performed in the United Kingdom." "We investigated the safety and immunogenicity of MVA85A in mycobacteria-exposed--but...
Source: Vaccine Weekly (2008-09-03)
|
